Smaller drug developers are increasingly moving away from the traditional paths of creating their own infrastructure or partnering with a larger, vertically integrated pharma company. Instead, they are constructing virtual supply chains, comprising an ecosystem of globally dispersed partners responsible for manufacturing and distributing a product.
These virtual supply chains are often heavily siloed and localized, and usually prioritized by cost. From a logistics perspective, this presents two problems.

In this whitepaper, we examine why prioritizing cost over precision is simple false economy.

• How to quantify the costs that stem from an excursion incident
• Costs of excursions and logistical challenge prior and during the launch phases
• Mitigating the risk of excursion and countering the effects of fragmentation